glp-1 dpp 4 combination Why is therapy with Glucagon-like peptide-1 (GLP-1) and Dipeptidyl peptidase-4 (DPP-4) inhibitors not recommended? dpp-4_inhibitors [TUSOM | Pharmwiki]

Increasing the use of GLP-1 receptor agonists in our clinic has created more work for providers and requires additional staff and support to reduce this burden, Nguyen said

Quick Answer: GLP-1 medications reduce belly fat as part of overall weight loss but do not selectively target abdominal fat

The first head-to-head clinical trial (SURMOUNT-5, published in NEJM 2025) showed tirzepatide produced 20.2% average weight loss at 72 weeks versus 13.7% for semaglutide approximately 47% greater relative weight loss

It simply refers to the cosmetic changes that may happen when you lose fat while taking a GLP-1 drug

Third, clinicians should review contraindications carefully

Ideally, like the anti-GIP antibody in MariTide, it not only offers structural protection but also exhibits biological activity